Pathios Therapeutics Limited, a biotech company focused on the development of first-in-class therapies for cancer, has appointed experienced biotechnology industry executive, Paul G. Higham, as Chief Executive Officer (CEO). Higham brings over 20 years of C-level executive biotechnology company experience to Pathios, as the company prepares to enter clinical development with its first-in-class GPR65 antagonist. In conjunction with Higham’s appointment, Pathios’ founding CEO, Stua...